Association of baseline variables with mortality until last follow-up
| p Value (log-rank test) | |
| Age | 0.950 |
| Male | 0.548 |
| BMI | 0.182 |
| NYHA classification | 0.483 |
| Delivery route | 0.048 |
| AFIB/AFLUT | 0.018 |
| Significant CAD | 0.098 |
| Previous cardiac surgery | 0.820 |
| COPD | 0.009 |
| Diabetes mellitus | 0.182 |
| Dyslipidaemia | 0.428 |
| Hypertension | 0.961 |
| Peripheral vascular disease | 0.682 |
| Cerebrovascular disease | 0.063 |
| GFR | 0.172 |
| STS PROM score >10% | 0.017 |
| Log ES >20% | <0.001 |
| ES II >10.3% (Q4) | 0.016 |
| NTproBNP >4970.5 pg/mL (Q4) | 0.035 |
| OPN >990.5 ng/mL (Q4) | 0.002 |
| EF (category) | 0.778 |
| Systolic pulmonary hypertension | 0.238 |
| Aortic valve area | 0.387 |
| Preprocedural AR invasive ≥2 | 0.410 |
| Post-TAVI AR ≥2 | 0.153 |
| Acute kidney injury (VARC-2) | <0.001 |
| Acute kidney injury, stage 3 | <0.001 |
AFIB, atrial fibrillation; AFLUT, atrial flutter; AR, aortic regurgitation; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; ES II, EuroSCORE II; GFR, glomerular filtration rate; Log ES, logistic EuroSCORE; NTproBNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Association; OPN, osteopontin; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; VARC, Valve Academic Research Consortium-2.